Bio Med Sciences Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bio Med Sciences Inc.
Novo Pumps Up Heart Failure Prospects With Cardior Purchase
The Danish drugmaker is spending some of its semaglutide cash on a mid-stage RNA-based heart failure therapy developed by the German biotech.
Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
Market Intel: Intense Competition, Innovation Drive Healing Trends In Wound Care
The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.
What Entrepreneurs Want, Get, and Don't Get from VCs
What makes a health care VC stand out in the minds of entrepreneurs? According to a first-of-its-kind survey by Windhover, PricewaterhouseCoopers, Wilson Sonsini, and Applied Information Networks, the answer is value-added services. Entrepreneurs prize VCs who assist them, pre-financing, with constructive feedback and sharing of due diligence results. VCs do pretty well here. But they do less well on the more important post-financing criteria: helping their portfolio companies secure additional financing and recruit customers, partners, and employees.
Company Information
- Industry
- Medical Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice